Skip to main content
SpringerLink
Log in

Parkinsonmittel

  • Chapter
Arzneiverordnungs-Report 2006

  • 419 Accesses

Auszug

Levodopapräparate sind die führenden Vertreter der Parkinsonmittel. Sie haben 2005 weiter zugenommen und umfassen jetzt 40% des Verordnungsvolumens. An zweiter Stelle folgen die Dopaminrezeptoragonisten mit deutlichen Zunahmen der Nichtergolinderivate Pramipexol und Ropirinol. Die Verordnungen von Anticholinergika und Amantadin haben sich 2005 kaum geändert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arnold G, Kupsch A (2000): Hemmung der Catechol-O-Methyltransferase. Optimierung der dopaminergen Therapie beim idiopathischen Parkinsonsyndrom mit Entacapone. Nervenarzt 71: 78–83.

    Article  PubMed  CAS  Google Scholar 

  • Clarke CE (2004): A „cure“ for Parkinson’s disease: can neuroprotection be proven with current trial designs? Mov Disord 19: 491–498.

    Article  PubMed  Google Scholar 

  • Crosby NJ, Deane KH, Clarke CE (2003): Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003;(1):CD003468.

    Google Scholar 

  • Deane KH, Spieker S, Clarke CE (2004): Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004 Oct 18; (4): CD004554.

    Google Scholar 

  • Deutsche Gesellschaft für Neurologie (2003): Leitlinie Parkinson-Syndrome. www.dgn.org/168.0.html.

    Google Scholar 

  • European Medicines Agency (EMEA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar). Internet: www.emea.eu.int/pdfs/human/press/pus/1185404en.pdf

    Google Scholar 

  • Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999): Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52: 1908–1910.

    PubMed  CAS  Google Scholar 

  • Hattori N, Mizuno Y (2004): Pathogenetic mechanisms of parkin in Parkinson’s disease. Lancet 364: 722–724.

    Article  PubMed  CAS  Google Scholar 

  • Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K (2004): Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329: 593–599.

    Article  PubMed  CAS  Google Scholar 

  • Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003;(2):CD003735.

    Google Scholar 

  • Koller WC, Tse W (2004): Unmet medical needs in Parkinson’s disease. Neurology 62(Suppl 1): S1–8.

    PubMed  CAS  Google Scholar 

  • Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 311: 1602–1607.

    PubMed  CAS  Google Scholar 

  • Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y (2001): Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57: 1687–1694.

    PubMed  CAS  Google Scholar 

  • Mejer Nielsen B (1983): Tiapride in levodopa-induced involuntary movements. Acta Neurol Scand 67: 372–375.

    Article  PubMed  CAS  Google Scholar 

  • Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology (2006): Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66: 983–995.

    Article  PubMed  CAS  Google Scholar 

  • Parkinson Study Group (2000): Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 284: 1931–1938.

    Article  Google Scholar 

  • Parkinson Study Group (2002): Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653–1661.

    Article  Google Scholar 

  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484–1491.

    Article  PubMed  CAS  Google Scholar 

  • Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158.

    Article  PubMed  CAS  Google Scholar 

  • Siderowf A, Stern M (2003): Update on Parkinson disease. Ann Intern Med 138: 651–658.

    PubMed  Google Scholar 

  • Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson’s disease. Neurology 50(Suppl 6): S18–S22; discussion S44–S48.

    PubMed  CAS  Google Scholar 

  • The Parkinson Study Group (1993): Effects of tocopherol and deprenyl on the progression of disability in early parkinson’s disease. N Engl J Med 328: 176–183.

    Article  Google Scholar 

  • The Parkinson Study Group (2004a): Levodopa and the progression of Parkinson’s disease. N Engl J Med 351: 2498–2508.

    Article  Google Scholar 

  • The Parkinson Study Group (2004b): Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044–1053.

    Article  Google Scholar 

  • Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt P, Moerman C, Schoors D (2004): Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363: 1179–1183.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Prof.Dr. med. Ulrich Schwabe

Authors
  1. Prof.Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schwabe, U. (2007). Parkinsonmittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2006. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-34370-7_41

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-34370-7_41

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-34369-1

  • Online ISBN: 978-3-540-34370-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation